Close Menu

NEW YORK, Oct. 1 – Orchid BioSciences said Monday it had sold its SNPstream system for SNP scoring to Tepnel Life Sciences and made an equity investment in the Manchester, UK-based company.

Under the terms of the deal, Tepnel will also gain access to Orchid’s SNP databases and biochemistry and software kits. In exchange Orchid has acquired the option to evaluate some of Tepnel’s discoveries for possible commercialization.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.